Explaining the Prescription Drug Provisions in the Build Back Better Act
By Juliette Cubanski, Tricia Neuman, and Meredith Freed
Kaiser Family Foundation
On November 19, 2021, the House of Representatives passed H.R. 5376, the Build Back Better Act (BBBA), which includes a broad package of health, social, and environmental proposals supported by President Biden. The BBBA includes several provisions that would lower prescription drug costs for people with Medicare and private insurance and reduce drug spending by the federal government and private payers. These proposals have taken shape amidst strong bipartisan, public support for the government to address high and rising drug prices. CBO estimates that the drug pricing provisions in the BBBA would reduce the federal deficit by $297 billion over 10 years (2022-2031).
The key prescription drug proposals included in the BBBA would:
– Allow the federal government to negotiate prices for some high-cost drugs covered under Medicare Part B and Part D
– Require inflation rebates to limit annual increases in drug prices in Medicare and private insurance
– Cap out-of-pocket spending for Medicare Part D enrollees and other Part D benefit design changes
– Limit cost sharing for insulin for people with Medicare and private insurance
– Eliminate cost sharing for adult vaccines covered under Part D
– Repeal the Trump Administration’s drug rebate rule
This brief summarizes these provisions and discusses the expected effects on people, program spending, and drug prices and innovation. We incorporate the estimated budgetary effects released by CBO on November 18, 2021, and to provide additional context for understanding the expected budgetary effects, we point to past projections of similar legislative proposals from CBO and others. This summary is based on the legislative language included in the House-passed bill that may be modified as it moves through the Senate.
This article originally appeared on KFF.org. Click here to read the full brief.
Recent Posts
-
LTC pharmacies demand ‘sustainable’ payment model ahead of 2026 drug-pricing changes
Many of the nation’s long-term care pharmacies are going to fall below “break-even” and may be forced out of business without additional support when drug-pricing policy changes kick in, sector advocates warned Wednesday.
-
Senior Care Pharmacy Coalition Launches “Save Senior Rx Care” to Protect Senior Access to Life-Saving Medications and Services
Led by the Senior Care Pharmacy Coalition (SCPC), America’s long-term care (LTC) pharmacies are launching Save Senior Rx Care, a new campaign urging Congress to protect access to life-saving medications and services for the millions of Americans who need long-term care.
-
New Report Underscores Unique Role LTC Pharmacies Play in Serving Complex Needs of Medicare Beneficiaries in Long-Term Care
A new report from the Senior Care Pharmacy Coalition (SCPC), the nation’s leading voice for long-term care (LTC) pharmacies, and ATI Advisory (ATI) highlights the clinical and functional complexity faced by millions of Medicare beneficiaries residing in nursing facilities and assisted living.
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.